Amniotics granted Singapore patent for its amniotic fluid collection technology
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Amniotics (publ) (Nasdaq Stockholm: AMNI) announced today that the The Singapore Patents Registry has approved a patent application for the company’s amniotic fluid collection technology. This patent, no. 10201609919W, “Cells, methods and apparatuses for amniotic fluid collection and isolation of cells”, provides Amniotics with protection for this technology in Singapore at least until 2034.
– Singapore is a well-known hub for biotechnology in the Asia-Pacific region and is thus important for Amniotics patent strategy of its neonatal stem cell platform. The amniotic fluid collection technology and our corresponding medical device is a cornerstone of our technology as it provides sterile cell material protected from ambient air whilst being completely safe for mother and child. We wish to thank our legal associates at Potter Clarkson for making this application successful, says Marcus Larsson, CEO, Amniotics AB.